ADCYAP1 and Alzheimer disease: Overall, IN-PACAP administration significantly ameliorated Aβ-associated deficits in this mouse model, but as manipulation of APP secretases for AD therapies has been shown to be insufficient in reversing decades-long plaque deposition with clinically-significant patient benefits, it remains to be seen how effective IN-PACAP will be.